Full Access
Platelet and vessel associated prostacyclin and thromboxane A2/prostaglandin endoperoxide receptors
K. JASCHONEK,
C. P. MULLER,
Corresponding Author
K. JASCHONEK
Medizinische Klinik der Universität Tübingen, D-7400 Tübingen, FRG
2 Medizinische Klinik der Universität Tübingen, Otfried-Müller Straße 10, D-7400 Tübingen, FRGSearch for more papers by this authorC. P. MULLER
Medizinische Klinik der Universität Tübingen, D-7400 Tübingen, FRG
Search for more papers by this authorK. JASCHONEK,
C. P. MULLER,
Corresponding Author
K. JASCHONEK
Medizinische Klinik der Universität Tübingen, D-7400 Tübingen, FRG
2 Medizinische Klinik der Universität Tübingen, Otfried-Müller Straße 10, D-7400 Tübingen, FRGSearch for more papers by this authorC. P. MULLER
Medizinische Klinik der Universität Tübingen, D-7400 Tübingen, FRG
Search for more papers by this authorAbstract
Abstract. Synthetic stable analogues of thromboxane A2 (TXA2), cyclic endoperoxides (PGH2) and prostacyclin (PGI2) opened up new opportunities for investigating the mechanisms of action of these compounds. They proved to be useful pharmacological probes for characterizing PGI2 and TXA2/PGH2 receptors. Over the past few years, new synthetic antagonists with high specificity allowed the modulation of biological responses to endogenous eicosanoids. These compounds will, therefore, considerably promote our understanding of the biological function and significance of arachidonate metabolites. The present review summarizes current concepts that have arisen concerning platelet and vascular PGI2 and TXA2/PGH2 receptors, their transmembrane signal transduction, as well as their possible implications in the pathophysiology of cardiovascular disease.
Abbreviations:
-
- Cyclic AMP
-
- 3‘, 5’-adenosine-monophosphate
-
- IP3
-
- inositol-1, 4, 5-trisphosphate
-
- GTP
-
- guanosine-5-triphosphate
-
- G
-
- guanyl nucleotide binding regulatory proteins
-
- PGH2
-
- cyclic endoperoxides
-
- PG
-
- prostaglandin
-
- PGI2
-
- prostacycli;n
-
- PI
-
- phosphoinositide
-
- TXA2
-
- thromboxane A2.
References
- 1 Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418–27.
- 2 Willerson JT, Hillis LD, Winniford M, Buya LM. Speculation regarding mechanisms responsible for acute ischaemic heart disease syndromes. J Am Coll Cardiol 1986; 8: 245–50.
- 3 Lam JY, Chesebro JH, Steels PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 1987; 75: 243–8.
- 4 Houston D, Shepherd JT, Vanhoutte PM. Aggregating platelets cause direct contraction and endothelium dependent relaxation of isolated coronary arteries. J Clin Invest 1986; 78: 539–44.
- 5 Schmitz JM, Apprill PG, Buja LM, Willerson JT, Campbell WB. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischaemia. Circ Res 1985; 57: 223–31.
- 6 Ashton JH, Benedict CR, Fitzgerald C et al. Serotonin as mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572–8.
- 7 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and the blood-vessel wall. N Engl J Med 1979; 300: 1142–7.
- 8 Shepherd JT, Vanhoutte PM. Mechanisms responsible for coronary vasospasm. J Am Coll Cardiol 1986; 8: 50–4.
- 9 Fitzgerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc 1987; 46: 154–8.
- 10 Siegl AM, Smither JB, Silver MJ. Selective binding site for 3H-prostacyclin binding on platelets. J Clin Invest 1979; 63: 215–20.
- 11 Shepherd GL, Lewis PJ, Blair IA, de Mey C, MacDermot J. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br J Clin Pharmacol 1983; 15: 77–81.
- 12 Neri Serneri GG, Fortini A, Lombardi A, Modesti PA, Abbate R, Gensini GF. Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet 1984; ii: 838–41.
- 13
Jaschonek K,
Weisenberger H,
Karsch KR,
Renn W,
Daiss W,
Schenzle D.
Impaired platelet prostacyclin binding in acute myocardial infarction.
Lancet
1984; ii: 1341.
10.1016/S0140-6736(84)90851-1 Google Scholar
- 14 Jaschonek K, Faul C, Renn W. In vitro desensitization of platelet prostacyclin receptors and adenylate cyclase by iloprost ZK 36374). 6th International Conference on Prostaglandins and Related Compounds. Florence, June 1986: 469 (abstr).
- 15 Schillinger E, Prior G. Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem Pharmacol 1980; 29: 2297–9.
- 16 Lombroso M, Nicosia S, Paolctti R, Whittle BJR, Moncada S, Vane JR. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins 1984; 27: 321–33.
- 17 Hall JM, Strange PG. The use of a prostacyclin analogue, (3H) iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci Rep 1984; 4: 941–8.
- 18 Alt U, Leigh PJ, Wilkins AJ, Morris PK, MacDermot J. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol 1986; 22: 118–9.
- 19 Trist DG, Everett B, O'Leary M, Wood J. Prostacyclin and human platelets: evidence for a single receptor. 6th International Conference on Prostaglandins and Related Compounds. Florence, June 1986: 346 (abstr).
- 20 Town MH, Schillinger E, Speckenbach A, Prior G. Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue. Ciloprost, as radioactive ligand. Prostaglandins 1982; 24: 61–73.
- 21 Rücker W, Schrör K. Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochem Pharmacol 1983; 32: 2405–10.
- 22 Leigh PJ, Cramp WA, MacDermot J. Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem 1984; 259: 12431–6.
- 23 Eggerman TL, Hartzell CJ, Selfe S, Andersen NH. The single prostacyclin receptor of gel-filtered platelets provides a correlation with antiaggregatory potency of PGI2 mimics. Thromb Res 1987; 45: 645–59.
- 24 Jaschonek K, Weisenberger H, Tidow S, Daiss W, Renn W, Ostendorf P. Platelet prostacyclin binding in smokers. J Lab Clin Med 1986; 108: 88–95.
- 25 Siegl AM, Smith JB, Silver MJ. Specific binding sites for prostaglandin D2 on human platelets. Biochem Biophys Res Commun 1979; 90: 291–6.
- 26 Cooper B, Ahern D. Characterization of the platelet prostaglandin D2 receptor. J Clin Invest 1979; 64: 586–90.
- 27 MacIntyre DE, Gordon JL. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb Res 1977; 11: 705–13.
- 28 Tynan S, Anderson NH, Wills MT, Harker LA, Hanson SR. On the multiplicity of platelet prostaglandin receptors. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs. Prostaglandins 1984; 27: 683–96.
- 29 Horne W. Desacetyl-l-nantradol: a selective prostaglandin antagonist. Prostaglandins Leukotrienes Med 1984; 15: 129–36.
- 30 Keery RJ, Lumley P. AH 6809, a selective antagonist at the human DP-receptor Br J Pharmacol Suppl, 1986: 286 P.
- 31 Jaschonek K, Renn W, Weisenberger H. The binding of 6-oxoprostaglandin E1 to platelet prostanoid receptors. Prostaglandins Leukotrienes Med 1986; 24: 79–86.
- 32 Oliva D, Bernini F, Corsini A, Nicosia S. 6-keto-prostaglandin E1 sensitive adenylate cyclase and binding sites in membranes from platelets and smooth muscle cells. Biochem Pharmacol 1984; 33: 3755–8.
- 33 Eggerman T, Andersen N, Robertson RP. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets. J Pharmacol Exp Ther 1986; 236: 568–70.
- 34 Wong PYK, Sun FF, McGiff JC. Metabolism of prostacyclin in blood vessels. J Biol Chem 1978; 253: 5555–7.
- 35 Whittle BJR, Moncada S. Platelet actions of stable carbocyclic analogues of prostacyclin. Circulation 1985; 72: 1219–25.
- 36 Corsini A, Folco GC, Fumagalli R, Nicosia S, Noe MA, Oliva D. (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol 1987; 90: 255–61.
- 37 Coleman RA, Humphrey PPA, Kennedy I, Lumley P. Prostanoid receptors–the development of a working classification. Trends Pharmacol Sci 1984; 5: 303–6.
- 38 Mais D, Burch RM, Saussy DL, Kochel PJ, Halushka PV. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. J Pharmacol Exp Ther 1985; 235: 729–34.
- 39 Hung SC, Ghali NI, Venton DL, Le Breton GC. Specific binding of the thromboxane A2 antagonist 13-azaprostananoic acid to human platelet membranes. Biochim Biophys Acta 1983; 728: 171–8.
- 40 Halushka PV, MacDermot J, Knapp DR et al. A novel approach for the study of thromboxane A2 and prostaglandin H2 receptors using an 1251-labelled ligand. Biochem Pharmacol 1985; 34: 1165–70.
- 41 Saussy D, Mais D, Burch R, Halushky PV. Identification of a putative TXA2/PGH2 receptor in human platelet membranes. J Biol Chem 1986; 261: 3025–9.
- 42 Burch R, Mais DE, Saussy DL, Halushka PV. Solubilization of a thromboxane A2/prostaglandin H2 antagonist binding site from human platelets. Proc Natl Acad Sci USA 1985; 82: 7234–8.
- 43 Armstrong RA, Jones RL, Wilson NH. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol 1983; 79: 953–64.
- 44 Burch R, Mais D, Pepkowitz S, Halushka P. Hydrodynamic properties of a thromboxane A2 prostaglandin H2 antagonist binding site solubilized from human platelets. Biochem Biophys Res Commun 1985; 132: 961–8.
- 45 Harris DN, Hedberg A, Philipps MB, Michel IM, Goldenberg RJ, Liu ECK. 7-Oxabicycloheptane analogs: modulators of the arachidonate cascade. 6th International Conference on Prostaglandins and Related Compounds. Florence, June 1986: 167 (abstr).
- 46 Kattelman EJ, Venton DL, Le Breton GC. Characterization of U 46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13. 177, ONO 3708 and SQ 29,548). Thromb Res 1986; 1: 471–81.
- 47 Narumiya S, Okuma M, Ushikubi F. Binding of a radiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol 1986; 88: 323–31.
- 48 Mais DE, Burch RM, Oates JE jr, Knapp D, Halushka PV. Photoaffinity labelling of a TXA2/PGH2 binding site in human platelets. Biochem Biophys Res Commun 1986; 140: 128–33.
- 49 Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976; 193: 163–5.
- 50 Gorman RR, Maxey KM, Bundy GL. Inhibition of human platelet thromboxane synthethase by 11a-carbathromboxane A2 analogs. Biochem Biophys Res Commun 1981; 100: 184–90.
- 51 Lefer AM, Smith EF III, Smith JB et al. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA 1980; 77: 1706–10.
- 52 Mais D, Saussy D, Chaikhouni A et al. Pharmacologic characterization of human and canine thromboxane A2 prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther 1985; 233: 418–24.
- 53 Burke SE, Lefer AM, Nicolaou KC, Smith GM, Smith JB. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol 1983; 78: 287–92.
- 54 Chignard M, Vargaftig BB. Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur J Pharmacol 1976; 38: 7–18.
- 55 Jakobs KH, Minuth M, Bauer S, Grandt R, Greiner C, Zubun P. Dual regulation of adenylate cyclase. A signal transduction mechanism of membrane receptors. Basic Res Cardiol 1986; 81: 1–9.
- 56 Best LC, Martin TJ, Russell RG, Preston FE. Prostacyclin increases cyclic AMP levels and adenylate cyclase in platelets. Nature 1977; 267: 850–2.
- 57 Mills DCB, MacFarlane DE. Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb Res 1974; 5: 401–12.
- 58 Steer ML, Wood A. Regulation of human platelet adenylate cyclase by epinephrine, prostaglandin E1 and guanine nucleotides. J Biol Chem 1979; 154: 10791–7.
- 59 Haslam RJ, Davidson ML, Desjardins JV. Inhibition of adenylate cyclase by adenosin analogues in preparations of broken and intact cells. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 1978; 176: 83–95.
- 60 Gorman RR, Fitzpatrick FA, Miller OV. Reciprocal regulation of human platelet cyclic AMP levels by thromboxane A2 and prostacyclin. Adv Cyclic Nucleotide Res 1978; 9: 597–609.
- 61 Best L, McGuire M, Martin T, Preston F, Russell R. Effects of epoxymethane analogues of prostaglandins endoperoxides on aggregation, on release of 5-hydrocytryptamine and on the metabolism of 3′, 5′-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta 583: 344–51.
- 62 Brass LF, Shaller CC, Belmonte EJ. Inositol 1, 4, 5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 1987; 79: 1269–75.
- 63 Exton JH. Role of calcium and phosphoinositides in the actions of certain hormones and neurotransmitters. J Clin Invest 1985; 75: 1753–7.
- 64 Pollock WK, Armstrong RA, Brydron LJ, Jones RL, Maclntyre DE. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Biochem J 1984; 219: 833–42.
- 65 Siess W, Boehlig B, Weber P, Lapetina E. Prostaglandin endoperoxide analogues stimulate phospholipase C and protein phosphorylation during platelet shape change. Blood 1985; 65: 1141–8.
- 66 Lapetina EG, Billah MM, Cuatrecasas P. The phosphatidylinositol cycle and the regulation of arachidonic acid production. Nature 1981; 292: 367–9.
- 67 Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. Lysophosphatic acids. Influence on platelet aggregation and intracellular calcium flux. Am J Pathol 1979; 96: 423–38.
- 68 Israels SJ, Robinson P, Docherty JC, Gerrard JM. Activation of permeabilized platelets by inositol 1, 4, 5-trisphophate. Thromb Res 1985; 40: 499–509.
- 69 Nishizuka Y. The role of proteinkinase C in cell surface signal transduction and tumor cell promotion. Nature 1984; 308: 693–8.
- 70 Berridge MJ. Inositoltrisphosphate and diacylglycerol as second messengers. Biochem J 1985; 220: 345–60.
- 71 Sano K, Takai Y, Yamanashi J, Nishizuka Y. A role of calcium-activated phospholipid dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. J Biol Chem 1983; 258: 2010–3.
- 72 Katada T, Gilman A, Watanabe Y, Bauer S, Jakobs KH. Protein-kinase C phosphorylates the inhibitory guanine nucleotide binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem 1985; 151: 431–7.
- 73 Maclntyre DE, McNicol A, Drummond AH. Tumor-promoting phorbol esters inhibit agonist-induced phosphatidate formation and Ca2+ flux in human platelets. FEBS Lett 1985; 180: 160–4.
- 74 Hopple S, Bushfield M, Murdoch F, Maclntyre DE. Regulation of platelet cAMP formation by protein kinase C. Thromb Haemostas 1987; 58: 463 (abstr).
- 75 Haslam RJ, Davidson MML. Guanine nucleotides decrease the free Ca2+ required for secretion of serotonin from permeabilized blood platelets. Evidence of a role for a GTP-binding protein in platelet activation. FEBS Lett 1984; 174: 90–5.
- 76 Brass L, Laposota M, Banga H, Rittenhouse S. Regulation of the phosphoinositide hydrolysis pathway in thrombin stimulated platelets by a pertussis toxin-sensitive guanine nucleotide binding protein. J Biol Chem 1986; 261: 16838–47.
- 77 Rybicki JP, Venton DL, Le Breton GC. The thromboxane antagonist, 13-azaprostanoic acid, inhibits arachidonicinduced Ca2+ release from isolated platelet membrane vesicles. Biochim Biophys Acta 1983; 751: 66–73.
- 78 Kaibuchi K, Tsuda K, Kikuchi A, Tanimoto T, Takai Y. Enhancement of collagen-induced phosphoinositide turnover by thromboxane A2 analogue through Ca2+ mobilization in human platelets. FEBS Lett 1985; 192: 104–8.
- 79 Gomperts BD. Involvement of guanine nucleotide-binding protein in the gating of Ca2+ by receptors. Nature 1983; 306: 64–6.
- 80 Jaschonek K, Karsch KR, Weisenberger H, Tidow S, Faul C, Renn W. Platelet prostacyclin binding in coronary artery disease. J Am Coll Cardiol 1986; 8: 259–66.
- 81 Sinha AK, Wilson DA, Mueller HS. Impaired prostacyclin (PGI2) receptor function in acute ischemic heart disease in man. J Am Coll Cardiol 1987; 9 (abstr).
- 82 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986; 315: 983–9.
- 83 Sinzinger H, Silberbauer K, Horsch AK, Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease — a rebound phenomenon. Prostaglandins 1981; 21: 49–51.
- 84 Reele SB, Miller OV, Spillers C, Gorman RR. The effects of continuous infusion of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation and cyclic AMP levels in normal volunteers. Prostaglandins 1983; 25: 287–302.
- 85 Edwards R, MacDermot J, Wilkins A. Prostacyclin analogues reduce ADP-ribosylation of the α-subunit of the G5-protein and diminish adenosine (A2) responsiveness of platelets. Br J Pharmacol 1987; 90: 501–10.
- 86 Jaschonek K, Faul C, Schmidt H, Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of platelet adenylate cyclase Eur J Pharmacol, in press.
- 87 Muller CP, Krueger GFR. Modulation of membrane proteins by vertical phase separation and membrane lipid fluidity. Basis for a new approach to tumor immunotherapy. Anticancer Res 1986; 6: 1181–94.
- 88 Borochov H, Shinitzky M. Vertical displacement of membrane proteins mediated by changes in microviscosity. Proc Natl Acad Sci USA 1976; 73: 4526–30.
- 89 Kury PG, Ramwell P, McConnell HM. The effect of prostaglandin E1 and E2 on the human erythrocyte as monitored by spin labels. Biochem Biophys Res Commun 1974; 56: 478–83.
- 90 Kury PG, McConnell HM. Regulation of membrane flexibility in human erythrocytes. Biochemistry 1975; 14: 2798–803.
- 91 Dave JR, Knazek RA. PGI2 modifies both prolactin binding capacity and fluidity of mouse liver membranes. Proc Natl Acad Sci USA 1980; 77: 6597–600.
- 92 Fitzgerald GA, Reilly I, Pedersen AK. The biochemical pharmacology of thromboxane synthetase inhibition in man. Circulation 1985; 72: 1194–201.
- 93 Aiken JW, Shebuski RJ, Miller OV, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 1981; 219: 299–308.
- 94 Schrör K, Smith EF, Bickerton M et al. Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol 1980; 238: H87–92.
- 95 Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EF, Lefer AM. Synthesis and biological properties of pinane TXA2 (PTA2) a selective inhibitor coronary artery constriction, platelet aggregation and thromboxane formation. Proc Natl Acad Sci USA 1979; 76: 2566–70.
- 96 Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH. Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol 1985; 84: 595–607.
- 97 Harris DN, Greenberg R, Philipps M et al. Effects of SQ 27427, a thromboxane A2 receptor antagonist, in the human platelet isolated smooth muscle. Eur J Pharmacol 1984; 103: 9–18.
- 98 Armstrong RA, Jones RL, Leigh PJ, MacDermot J, Wilson NH. Novel prostaglandin endoperoxide analogues which block thromboxane receptors and mimic prostacyclin. Br J Pharmacol Suppl 1985; 86: 643.
- 99 Ogletree M, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435–41.
- 100 Le Breton GC, Venton DL, Enke SE, Halushka PV. 13-azaprostanoic acid: a specific antagonist of the human platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci USA 1979; 76: 4097–100.
- 101 Jones RL, Wilson NH, Armstrong RA, Peesapati V, Smith GM. Effects of thromboxane antagonist EP 045 on platelet aggregation. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 11: 345–50.
- 102 Stegmeier K, Pill J, Müller-Beckmann B. The pharmacological profile of the thromboxane A2 antagonist BM 13. 177. A new antiplatelet and anti-thrombotic drug. Thrombosis Res 1984; 35: 379–95.
- 103 Brittain RT, Boutal L, Carter MC et al. AH 23848:a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation 1985; 72: 1208–18.
- 104 Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986; 77: 496–502.
- 105 Wainwright CL, Parratt JR. Antiarrhythmic effects of the thromboxane antagonist BM 13. 177. Eur J Pharmacol 1987; 133: 257–64.
- 106 Brezinski ME, Yanagisawa A, Darius H, Lefer AM. Antiischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Am Heart J 1985; 110: 1161–7.
- 107 Ashton JH, Ogletree M, Taylor AL et al. A thromboxane A2 antagonist, SQ 29,548, abolishes or attenuates cyclic flow variations in severely narrowed canine coronary arteries. Circulation 1985; 72 (Suppl III): 273 (abstr).
- 108 Lane IF, Irwin JTC, Poskish KR, Greenhalgh RM, McCollum, CN. Thromboxane antagonists: reduction of platelet deposition on human grafts in vivo. Thromb Haemost 1985; 54: 3 (abstr).
